An Open-Label Trial to look at the long-term safety and effectiveness ofBrivaracetam used in addition to the subjects main treatment in subjectsaged 16 years or older with epilepsy

• Conditions: onpyschotic Behavioural Side Effects in Subjects With Epilepsy; MedDRA version: 14.1Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disorders; Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

• Registration Number: EUCTR2012-000827-42-IT
• Lead Sponsor: CB PHARMA SA/NV.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-06-08
• Last Update Posted: 27 January 2014

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 650

Inclusion Criteria

1. An Independent Ethics Committee (IEC)/Institutional Review Board (IRB) approved written Informed Consent form is signed and dated by the subject or by the parent(s) or legal representative. The Informed Consent form or a specific Assent form, where required, will be signed and dated by minors. 2.Subject is male or female and 16 years or older. Subjects under 18 years of age may be included only where legally permitted and ethically accepted. 3. Subjects having completed the Treatment Period of N01394, or N01395, or other planned BRV Phase 3b studies in epilepsy, and have access to the present study. 4. Subject for whom the Investigator believes a reasonable benefit from the long-term administration of BRV may be expected. 5 Female subjects without childbearing potential (postmenopausal for at least 2 years, bilateral oophorectomy or tubal ligation, complete hysterectomy) are eligible. Female subjects with childbearing potential are eligible if they use a medically accepted contraceptive method. Oral or depot contraceptive treatment with at least ethinylestradiol 30µg, monogamous relationship with vasectomized partner, or double-barrier contraception are acceptable methods. Abstinence will be considered as an acceptable method of contraception if the Investigator can document that the subject agrees to be compliant. . 6 Subject/legally acceptable representative considered as reliable and capable of adhering to the protocol, visit schedule, or medication intake according to the judgment of the Investigator.
Are the trial subjects under 18? yes
Number of subjects for this age range: 13
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 624
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 13

Exclusion Criteria

• Hypersensitivity to any components of the investigational medicinal product (IMP) or comparative drugs as stated in this protocol during the course of the prior study. • Severe medical, neurological, or psychiatric disorders, or laboratory values that may have an impact on the safety of the subject. • Poor compliance with the visit schedule or medication intake in the previous BRV study. • Planned participation in any other clinical study of another investigational drug or device during this study. • Pregnant or lactating woman. • Any medical condition which, in the Investigator’s opinion, warrants exclusion. • Lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response (Yes”) to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at the last visit of the previous study or at the EV of N01372 if not completed at the last visit of the previous study.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Timepoint(s) of evaluation of this end point: Occurrence of a TEAE, 'Withdrawal due to an AE' and 'Occurrence of an SAE' ongoing on a daily basis. Laboratory tests (hematology, blood chemistry, urinalysis), and Vital signs (systolic blood pressure, diastolic blood pressure, pulse rate) every 3 months; and body weight, ECG, and Physical and neurological examinations every 6 months.;Main Objective: To evaluate the long-term safety and tolerability of BRV at individualized doses up to a maximum of 200mg/day as adjunctive treatment in adult subjects with epilepsy.;Secondary Objective: To evaluate the maintenance of efficacy of BRV over time;Primary end point(s): To evaluate the long-term safety and tolerability of BRV at individualized doses up to a maximum of 200mg/day as adjunctive treatment in adult subjects with epilepsy.